Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease

Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease

Mounting evidence indicates that sclerostin, a well-known inhibitor of bone formation, may qualify as a clinically relevant biomarker of chronic kidney disease-related mineral and bone disorder (CKD-MBD), including abnormal mineral and bone metabolism and extraskeletal calcification. For this purpos...

Full description

Bibliographic Details
Main Authors: Annelies De Maré, Anja Verhulst, Etienne Cavalier, Pierre Delanaye, Geert J Behets, Bjorn Meijers, Dirk Kuypers, Patrick C D’Haese, Pieter Evenepoel
Format: Article
Language:English
Published: MDPI AG 2019-11-01
Series:Journal of Clinical Medicine
Subjects:
sclerostin
end-stage kidney disease
bone turnover
circulating sclerostin
Online Access:https://www.mdpi.com/2077-0383/8/12/2027

Internet

https://www.mdpi.com/2077-0383/8/12/2027

Similar Items